Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

CNBC's Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk...

As March 2024 draws near, the performance of the S&P 500 Index is starting to reveal itself, with some stocks demonstrating notable growth while others show potential for valuation increases in the...

Eli Lilly 's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.

A rival's weight-loss drug candidate did well in a mid-stage clinical trial. The treatment met all of its endpoints in the study.

'Mad Money' host Jim Cramer looks at the current class of $1 trillion stocks and looks at what stocks could be poised to join the group.

Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions com...

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

Eli Lilly's sales and profits are likely to be boosted by new treatments for diabetes, weight loss, and potentially Alzheimer's. The stock's valuation is pricey, but it could look cheap years from ...

An analyst downgraded the pharmaceutical mainstay's shares. He now feels the company is only a hold; previously, he tagged it as worthy of a buy.

Eli Lilly is enjoying impressive revenue growth fueled by high demand for its diabetes treatments. However, the company also develops medications for cancer, plaque psoriasis, and obesity.

Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.

The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose injection pen, according to...

With the coveted trillion-dollar valuation, a new pinnacle of success is approaching for a limited number of companies. This once-impossible milestone is now within reach for three formidable poten...